Excess in the pharmaceutical industry

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 12, 2004, Pages 1451-1453

  Angell, Marcia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPETITION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; MEDICAL PRACTICE; PROFIT; SHORT SURVEY;

EID: 10644283148     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1041594     Document Type: Short Survey

References (12)

1. Pattison N, Warren L. 2002 drug industry profits: hefty pharmaceutical company margins dwarf other industries. Washington (DC): Public Citizen Congress Watch; June 2003. Available: www.citizen.org/documents/Pharma_Report .pdf (accessed 2004 Nov 3).
2. Fortune 500: How the industries stack up. Fortune 2004;149(7):F26.
3. Bouton D, editor. Out-of-bounds: rising prescription drug prices for seniors. Publ no 03-106. Washington (DC): Families USA; July 2003. Available: www.familiesusa.org (accessed 2004 Nov 4).
4. Hensley S. Drug prices rise at faster clip, placing burden on consumers. Wall Street Journal 2003 Apr 15;Sect D:4.
5. US Food and Drug Administration Center for Drug Evaluation and Research, Department of Health and Human Services. NDAs approved in calendar years 1990-2003 by therapeutic potentials and chemical types. Jan 21, 2004. Available: www.fda.gov/cder/rdmt/pstable.htm (accessed 2004 Nov 3).
6. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile 2002. Washington (DC): PhRMA; 2002. p. 79.
7. The Henry J. Kaiser Family Foundation. Prescription drug trends: a chartbook update. Publ no 3112. Menlo Park (CA): The Foundation; 2001. p. 45. Available: www.kff.org (accessed 2004 Nov 4).
8. Mahan D. Profiting from pain: where prescription drug dollars go. Publ no 02-105. Washington (DC): Families USA; July 2002. Available: www.familiesusa.org (accessed 2004 Nov 4).
9. Harris G. As a patent expires, drug firm lines up pricey alternative. Wall Street Journal 2002 Jun 6;Sect A:1.
10. Relman A. Separating continuing medical education from pharmaceutical marketing. JAMA 2001;285:2009-12.
11. Aaron C, Lincoln T. The other drug war 2003: Drug companies deploy an army of 615 lobbyists to protect profits. Washington (DC): Public Citizen Congress Watch; June 2003. Available: www.citizen.org/documents/ Other_Drug_War2003.pdf (accessed 2004 Nov 4).
12. Levit K, Smith C, Cowan C, Sensenig A, Catlin A. Health spending rebound continues in 2002. Health Aff 2004;23:147-59.